Asking patients to write letters illuminates new aspects of the physician-patient-family relationship
In 2019, we (authors SM, LC) initiated a research study on the experience of care partners of people with Parkinson’s disease psychosis (PDP). Among other activities, participants wrote a letter to their care recipient’s doctor to the prompt: “Understanding that you know the most about this person, specifically their PD psychosis because you likely spend the most time with them (certainly more time than the doctor gets to spend with them), what details would you share?” Here, we present one letter, written by author LAD, followed by a short response by author SM, a specialist in movement disorders and narrative medicine.
Parkinson s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., May 5, 2021 /PRNewswire/ Parkinson s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing ( dopaminergic ) neurons in a specific area of the brain called substantia nigra. Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. According to the Parkinson s Foundation, people with PD may experience: tremors, mainly at rest and described as pill rolling tremor in hands, plus gait and balance problems. The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson s itself is not fatal, disease complications can be serious. The Centers for Disease Control and Prevention (CDC) rated complications from PD as the 14th cause of
More OFF Time and Dyskinesia Education Needed, Survey Suggests
Adamas Pharmaceuticals Inc launches the education campaign “Picture More Time” in response to a survey suggesting the need for education in the Parkinson’s community about OFF time and dyskinesia.
An Incomplete Understanding
The survey, co-sponsored by the Parkinson & Movement Disorder Alliance (PMD Alliance) and Adamas, received 775 respondents, including 527 people with PD and 248 care partners. Seventy-eight percent of those surveyed reported an incomplete understanding of OFF time and dyskinesia.
The results also showed that people with PD and care partners find these motor complications challenging, as well as stigmatizing and socially disabling, a media release from Adamas Pharmaceuticals Inc explains.
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., April 20, 2021 /PRNewswire/ While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic. According to various reports the outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology, in January 2021, the population with dementia are at high risk of contracting COVID-19 infection as the cognitive symptoms cause difficulty to abide by the safety guidelines that were proposed to contain the viral spread. Furthermore, older populations with dementia are also more likely to have more severe disease consequences than those without dementia. Additionally, the statement from